Transgene S.a.

Hélène Haegel

Michel Geist

Christine Thioudellet

Benoît Grellier

Jean-Baptiste Marchand

Rémy Hallet

Rêmy Hallet

The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.

Antibody against the CSF-1R

The invention is generally directed to promoting dendritic cells (DCs), and optionally M1-type (macrophage M1 polarization), immune response by administering a compound that modulates macrophage polarization. The invention is directed to the use of an antibody able to bind to CSF-1R for modulating macrophage polarization. The invention is also directed to methods for evaluating the dose efficacy of an antibody able to bind to CSF-1R in a patient by assessing the in vivo or in vitro polarization of macrophages. The invention is further directed to post-treatment companion test and assays to assess the effect of an antibody able to bind to CSF-1R on a subject being treated.

In vitro generation of dendritic cells by exposure to an anti-CSF1-R antibody

The invention is generally directed to promoting M1-type (macrophage M1 polarization) immune response by administering a compound that modulates macrophage activation. The invention is directed to the use of an antibody able to bind to CSF-IR for modulating macrophage activation. The invention is also directed to methods for evaluating the dose efficacy of an antibody able to bind to CSF-IR in a patient by assessing the in vivo or in vitro activation of macrophages. The invention is further directed to post-treatment companion test and assays to assess the effect of an antibody able to bind to CSF-IR on a subject being treated.

Growing community of inventors

Strasbourg, France

Hélène Haegel